HWK-007

Whitehawk Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	HWK-007
Also known as	HWK-007 anti-PTK7 targeted ADC
Sponsor	Whitehawk Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

HWK-007 CI brief — competitive landscape report
HWK-007 updates RSS · CI watch RSS
Whitehawk Therapeutics, Inc. portfolio CI